Wang KY, et al. - Researchers tested omalizumab's safety and efficacy in improving asthma outcomes in a series of pediatric patients who were initiated on omalizumab despite an immunoglobulin E (IgE) level higher than the age-indicated therapeutic windows. They analyzed patient charts to determine the number of asthma-related events in the 12 months before and after initiation of omalizumab and the Asthma Control Test scores at the time of initiation and at 12 months of therapy. Based on the findings, they concluded that omalizumab may be safely used in pediatric patients with IgE levels higher than the indicated therapeutic windows.